-
-
-
-
Description
- Semisynthetic D-amino acid decapeptide derived from HLA class I B2702
-
-
Target Organism
-
- No MICs found on DRAMP database
-
Reference
-
- Potential of immunomodulatory host defense peptides as novel anti-infectives.Trends in Biotechnology(2009).(PMID: 19683819)
- RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.Inflamm. Bowel Dis.(2005)(PMID: 16043985)
-
Medical use
- Inflammatory bowel disease
-
Company
- Genzyme; licensed to Procter&Gamble
-
Stage of Development
- Post Phase II
-
- A protease-resistant, d-amino acid-containing peptide with similar efficacy to asacol; attempting to improve activity through formulation.
-
Clinical Trials
- 2004-004077-29(EudraCT)